Boundless Bio (BOLD) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for Boundless Bio (BOLD).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||
Research And Development | 9.73M (-0.92%) | 9.82M (-7.97%) | 11M (-12.68%) | 12M (+0.66%) | 12M (-8.79%) | 13M (-5.54%) | 14M (-4.41%) | 15M (+12.26%) | 13M (+26.13%) | 10M (-10.64%) | 12M (+5.14%) | 11M (+16.63%) | 9.50M |
Selling General And Administrative | 4.74M (+13.13%) | 4.19M (-6.26%) | 4.47M (-7.64%) | 4.84M (-6.92%) | 5.20M (+4.84%) | 4.96M (+7.13%) | 4.63M (-0.64%) | 4.66M (+24.27%) | 3.75M (+10.95%) | 3.38M (+2.11%) | 3.31M (+14.53%) | 2.89M (+12.02%) | 2.58M |
Operating Expenses | 14M (+3.43%) | 14M (-7.59%) | 15M (-11.20%) | 17M (-1.61%) | 17M (-5.14%) | 18M (-2.35%) | 19M (-3.46%) | 19M (+14.87%) | 17M (+22.32%) | 14M (-7.69%) | 15M (+7.09%) | 14M (+15.47%) | 12M |
Depreciation And Amortization | 280K (-15.15%) | 330K (+10.00%) | 300K (0.00%) | 300K (-6.25%) | 320K (+45.45%) | 220K (-26.67%) | 300K (0.00%) | 300K (+15.38%) | 260K (-27.78%) | 360K (+80.00%) | 200K (0.00%) | 200K (0.00%) | 200K |
Operating Income | |||||||||||||
Operating Income | -14.47M (+3.36%) | -14.00M (-7.59%) | -15.15M (-11.20%) | -17.06M (-1.61%) | -17.34M (-5.14%) | -18.28M (-2.30%) | -18.71M (-3.51%) | -19.39M (+14.87%) | -16.88M (+22.32%) | -13.80M (-7.69%) | -14.95M (+7.09%) | -13.96M (+15.47%) | -12.09M |
Ebit | -14.47M (+3.36%) | -14.00M (-7.59%) | -15.15M (-11.20%) | -17.06M (-1.61%) | -17.34M (-5.14%) | -18.28M (-2.30%) | -18.71M (-3.51%) | -19.39M (+14.87%) | -16.88M (+22.32%) | -13.80M (-7.69%) | -14.95M (+7.09%) | -13.96M (+15.47%) | -12.09M |
EBITDA | -14.19M (+3.80%) | -13.67M (-7.95%) | -14.85M (-11.40%) | -16.76M (-1.53%) | -17.02M (-5.71%) | -18.05M (-1.96%) | -18.41M (-3.56%) | -19.09M (+14.86%) | -16.62M (+23.66%) | -13.44M (-8.88%) | -14.75M (+7.19%) | -13.76M (+15.73%) | -11.89M |
Other Income / Expenses | |||||||||||||
Interest Income | 920K (-17.86%) | 1.12M (-11.81%) | 1.27M (-8.63%) | 1.39M (-12.58%) | 1.59M (-17.19%) | 1.92M (-11.52%) | 2.17M (-8.82%) | 2.38M (+67.61%) | 1.42M (-10.69%) | 1.59M (-9.14%) | 1.75M (+12.90%) | 1.55M (+287.50%) | 400K |
Net Interest Income | 920K (-17.86%) | 1.12M (-11.81%) | 1.27M (-8.63%) | 1.39M (-12.58%) | 1.59M (-17.19%) | 1.92M (-11.52%) | 2.17M (-8.82%) | 2.38M (+67.61%) | 1.42M (-10.69%) | 1.59M (-9.14%) | 1.75M (+12.90%) | 1.55M (+287.50%) | 400K |
Other Non Operating Income | 920K | - | - | - | - | 10K (-66.67%) | 30K (0.00%) | 30K (0.00%) | 30K (-62.50%) | 80K (+166.67%) | 30K (+200.00%) | 10K | -30.00K |
Net Income | |||||||||||||
Net Income From Continuing Operations | -13.55M (+5.20%) | -12.88M (-7.20%) | -13.88M (-11.42%) | -15.67M (-0.57%) | -15.76M (-4.19%) | -16.45M (-0.36%) | -16.51M (-2.77%) | -16.98M (+10.05%) | -15.43M (+27.10%) | -12.14M (-7.82%) | -13.17M (+6.21%) | -12.40M (+5.80%) | -11.72M |
Net Income | -13.55M (+5.20%) | -12.88M (-7.20%) | -13.88M (-11.42%) | -15.67M (-0.57%) | -15.76M (-4.19%) | -16.45M (-0.36%) | -16.51M (-2.77%) | -16.98M (+10.05%) | -15.43M (+27.10%) | -12.14M (-7.82%) | -13.17M (+6.21%) | -12.40M (+5.80%) | -11.72M |
Comprehensive Income Net Of Tax | -13.64M (-76.58%) | -58.25M (+321.49%) | -13.82M (-12.03%) | -15.71M (-0.88%) | -15.85M (-75.72%) | -65.28M (+302.71%) | -16.21M (-4.76%) | -17.02M (+9.88%) | -15.49M (-68.39%) | -49.00M (+272.62%) | -13.15M (+5.88%) | -12.42M (+8.57%) | -11.44M |